Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients
CompletedNot applicableNCT03742466
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Carpal tunnel syndrome is a common peripheral entrapment neuropathy, this study aims to investigate if, and to what extent local ozone therapy could offer symptom improvement in scleroderma patients with Carpal tunnel syndrome
Study details
- Official title
- Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients. A Single-blind Randomized Clinical Trial
- Conditions
- Carpal Tunnel Syndrome
- Chronic Pain
- Scleroderma
- Interventions
- Drug: Ozone
- Drug: methylprednisolone acetate
- Sponsor
- Assiut University
- Start date
- 2018-11-10
- Primary completion
- 2019-07-30
- Sex
- All
- Age range
- from 20 Years to 60 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * adult patients with scleroderma * complaining of carpal tunnel syndrome of 3-month duration or more * diagnosed axonal neuropathy using electrodiagnosis, nerve conduction study Exclusion Criteria: * patient refusal * infection at the site of intervention * previous injection in the recent 3 months * Coagulopathy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03742466